University’s Alzheimer’s Treatment Gets Clinical Trial Without Industry Partner

University’s Alzheimer’s Treatment Gets Clinical Trial Without Industry Partner
The Vanderbilt University Medical Center has passed a key hurdle in its quest to develop a treatment for Alzheimer's disease with the announcement that the U.S. Food and Drug Administration (FDA) has approved a Phase 1 clinical trial of the therapy. The development marks one of the few times that a university has taken a treatment from discovery to the first clinical trial without the support of a pharmaceutical company. "The movement to the clinical phase of the research is the result of tireless colleagues reaching across disciplines in pursuit of the shared goal of hoping to someday improve the lives of individuals with Alzheimer's disease and possibly other brain disorders, such as schizophrenia," Susan R. Wente, PhD, provost and vice chancellor for academic affairs, said in a press release. "This work exactly illustrates the critical role that basic science conducted in partnership with a world-class medical center can play in advancing knowledge in an attempt to fight a devastating disease," she added. Researchers want to know whether the compound they developed will selectively activate a key receptor in the brain, as they hope. "Importantly, at this early stage, the FDA has only granted permission to assess potential safety of this investigational new drug in healthy volunteers," said P. Jeffrey Conn, PhD, a professor of pharmacology at the Vanderbilt University School of Medicine and director of the Vanderbilt Center for Neuroscience Drug Discovery. If the drug proves safe, the research team will ask for a
Subscribe or to access all post and page content.

One comment

  1. Linda Grishman says:

    I hope this comes sooner rather than later. I am in the early stages of this perilous disease. I am second maternal generation suffering from early stages. Sadly it is worsening. I haven been on Aricept 10mg for years. Still, you can deduce that I am still quite cognizant. It’s my short term memory that plagues me even with my daily reminderss and app alarms. I am wondering if Mementine may be more beneficial. I do hope to receive a response from you. Thank you, Linda Grishman age 67. Burlington, VT

Leave a Comment

Your email address will not be published. Required fields are marked *